SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it has filed a response to the recent patent infringement lawsuit brought against it by CryoCath Technologies Inc., and confirmed that it does not believe that it infringes any valid and enforceable claim. The Company's answer to the suit was filed with the United States District Court for the District of Delaware.
Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "We are very confident in the strength of our intellectual property portfolio and continue to believe that this lawsuit is without merit. We have very carefully evaluated the claims in CryoCath's complaint and remain confident that we do not infringe any valid and enforceable claims. We will examine our options to leverage CryoCor's intellectual property position and what is in the best interests of our shareholders."
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor has completed enrollment in a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved in the United States for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com
Forward Looking Statements
The statements in this press release that are not descriptions of
historical facts are forward-looking statements that are subject to risks
and uncertainties. These include statements related to the Company's
intellectual property portfolio, the merits and likely outcome of the
CryoCath lawsuit, and actions CryoCor may take to leverage its intellectual
property position. The actual events or results may differ materially from
those projected in such forward-looking statements due to a number of
factors and the risks and uncertainties identified in the Company's filings
with the Securities and Exchange Commission, including risks and
uncertainties relating to its intellectual property. These forward-looking
statements speak only as of the date hereof. The Company expressly
disclaims any intent or obligation to update any of these forward-looking
CryoCor, Inc. The Ruth Group
Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors)
Chief Financial Officer (646) 536-7030 / 7020
(858) 909-2200 firstname.lastname@example.org
Jason Rando (media)
|SOURCE CryoCor, Inc.|
Copyright©2007 PR Newswire.
All rights reserved